Italia markets close in 4 hours 8 minutes

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
271,91+2,98 (+1,11%)
Alla chiusura: 04:00PM EDT
271,91 0,00 (0,00%)
Preborsa: 07:05AM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente268,93
Aperto270,00
Denaro271,91 x 100
Lettera272,05 x 100
Min-Max giorno269,84 - 273,14
Intervallo di 52 settimane211,71 - 329,72
Volume2.139.134
Media Volume2.945.091
Capitalizzazione145,846B
Beta (5 anni mensile)0,60
Rapporto PE (ttm)21,79
EPS (ttm)12,48
Prossima data utili02 mag 2024
Rendimento e dividendo (futuro)9,00 (3,31%)
Data ex dividendo16 mag 2024
Stima target 1A306,20
  • GlobeNewswire

    Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032

    PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic

  • GlobeNewswire

    Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease

    Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan’s proprietary target discovery